Suppr超能文献

用于复合终点的统计方法。

Statistical methods for composite endpoints.

机构信息

Department of Cardiology, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands.

出版信息

EuroIntervention. 2021 Apr 2;16(18):e1484-e1495. doi: 10.4244/EIJ-D-19-00953.

Abstract

Composite endpoints are commonly used in clinical trials, and time-to-first-event analysis has been the usual standard. Time-to-first-event analysis treats all components of the composite endpoint as having equal severity and is heavily influenced by short-term components. Over the last decade, novel statistical approaches have been introduced to overcome these limitations. We reviewed win ratio analysis, competing risk regression, negative binomial regression, Andersen-Gill regression, and weighted composite endpoint (WCE) analysis. Each method has both advantages and limitations. The advantage of win ratio and WCE analyses is that they take event severity into account by assigning weights to each component of the composite endpoint. These weights should be pre-specified because they strongly influence treatment effect estimates. Negative binomial regression and Andersen-Gill analyses consider all events for each patient -rather than only the first event - and tend to have more statistical power than time-to-first-event analysis. Pre-specified novel statistical methods may enhance our understanding of novel therapy when components vary substantially in severity and timing. These methods consider the specific types of patients, drugs, devices, events, and follow-up duration.

摘要

复合终点通常用于临床试验,而首次事件时间分析是常用的标准。首次事件时间分析将复合终点的所有组成部分视为具有同等严重程度,并且受到短期组成部分的严重影响。在过去十年中,已经引入了新的统计方法来克服这些限制。我们回顾了赢率分析、竞争风险回归、负二项回归、Andersen-Gill 回归和加权复合终点 (WCE) 分析。每种方法都有优点和局限性。赢率和 WCE 分析的优点是,它们通过为复合终点的每个组成部分分配权重来考虑事件的严重程度。这些权重应该预先指定,因为它们会强烈影响治疗效果的估计。负二项回归和 Andersen-Gill 分析考虑了每个患者的所有事件,而不仅仅是第一个事件,并且往往比首次事件时间分析具有更高的统计效力。当组成部分在严重程度和时间上有很大差异时,预先指定的新型统计方法可能会增强我们对新型治疗方法的理解。这些方法考虑了特定类型的患者、药物、设备、事件和随访时间。

相似文献

1
Statistical methods for composite endpoints.
EuroIntervention. 2021 Apr 2;16(18):e1484-e1495. doi: 10.4244/EIJ-D-19-00953.
3
Applying novel methods to assess clinical outcomes: insights from the TRILOGY ACS trial.
Eur Heart J. 2015 Feb 7;36(6):385-92a. doi: 10.1093/eurheartj/ehu262. Epub 2014 Jul 10.
4
A win ratio approach to the re-analysis of Multiple Risk Factor Intervention Trial.
Clin Trials. 2019 Dec;16(6):626-634. doi: 10.1177/1740774519868233. Epub 2019 Aug 7.
5
Comparative Methodological Assessment of the Randomized GLOBAL LEADERS Trial Using Total Ischemic and Bleeding Events.
Circ Cardiovasc Qual Outcomes. 2020 Aug;13(8):e006660. doi: 10.1161/CIRCOUTCOMES.120.006660. Epub 2020 Jul 30.
6
Impact of weighted composite compared to traditional composite endpoints for the design of randomized controlled trials.
Stat Methods Med Res. 2015 Dec;24(6):980-8. doi: 10.1177/0962280211436004. Epub 2012 Jan 24.
7
A systematic comparison of recurrent event models for application to composite endpoints.
BMC Med Res Methodol. 2018 Jan 4;18(1):2. doi: 10.1186/s12874-017-0462-x.
10
Win ratio approach for analyzing composite time-to-event endpoint with opposite treatment effects in its components.
Pharm Stat. 2022 Nov;21(6):1342-1356. doi: 10.1002/pst.2248. Epub 2022 Jun 29.

引用本文的文献

4
[[Use of a multistate model in survival predictions in cardiology studies]].
REC Interv Cardiol. 2025 Feb 24;7(1):44-50. doi: 10.24875/RECIC.M24000489. eCollection 2025 Jan-Mar.
5
Adolescent Obesity and Charlson Comorbidity Index in Young Adults.
J Clin Med. 2025 Jan 28;14(3):873. doi: 10.3390/jcm14030873.
7
Making Sense of Composite Endpoints in Clinical Research.
J Clin Med. 2023 Jun 29;12(13):4371. doi: 10.3390/jcm12134371.
9
Reply: Composite endpoints in clinical trials - simplicity or perfection?
EuroIntervention. 2022 Jan 28;17(13):1121-1122. doi: 10.4244/EIJ-D-21-00440R.
10
Letter: Composite endpoints in clinical trials - simplicity or perfection?
EuroIntervention. 2022 Jan 28;17(13):1120. doi: 10.4244/EIJ-D-21-00440L.

本文引用的文献

1
Prosthetic Valve Endocarditis After TAVR and SAVR: Insights From the PARTNER Trials.
Circulation. 2019 Dec 10;140(24):1984-1994. doi: 10.1161/CIRCULATIONAHA.119.041399. Epub 2019 Nov 6.
2
Risk of Total Events With Icosapent Ethyl: Can We Reduce It?
J Am Coll Cardiol. 2019 Jun 11;73(22):2803-2805. doi: 10.1016/j.jacc.2019.03.492.
3
Effects of Icosapent Ethyl on Total Ischemic Events: From REDUCE-IT.
J Am Coll Cardiol. 2019 Jun 11;73(22):2791-2802. doi: 10.1016/j.jacc.2019.02.032. Epub 2019 Mar 18.
8
An alternative approach to confidence interval estimation for the win ratio statistic.
Biometrics. 2015 Mar;71(1):139-145. doi: 10.1111/biom.12225. Epub 2014 Aug 25.
9
Applying novel methods to assess clinical outcomes: insights from the TRILOGY ACS trial.
Eur Heart J. 2015 Feb 7;36(6):385-92a. doi: 10.1093/eurheartj/ehu262. Epub 2014 Jul 10.
10
Competing risks analyses: objectives and approaches.
Eur Heart J. 2014 Nov 7;35(42):2936-41. doi: 10.1093/eurheartj/ehu131. Epub 2014 Apr 7.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验